Cited by

• Cardiac and renovascular effects in the anaesthetized dog of BW A575C: a novel angiotensin converting enzyme inhibitor with beta-adrenoceptor blocking properties.

  Cambridge D, Whiting MV, Allan G. Cambridge D, et al. Br J Pharmacol. 1988 Jan;93(1):165-75. doi: 10.1111/j.1476-5381.1988.tb11418.x. Br J Pharmacol. 1988. PMID: 2894874 Free PMC article.
• Effects of chronic metoprolol and sulphinpyrazone on human lymphocyte beta-adrenoceptors.

  De Blasi A, Cortellaro M, Costantini C. De Blasi A, et al. Br J Clin Pharmacol. 1984 Jul;18(1):45-50. doi: 10.1111/j.1365-2125.1984.tb05020.x. Br J Clin Pharmacol. 1984. PMID: 6331481 Free PMC article.
• ISA--vasodilatation: improvement of organ perfusion.

  Hansson L. Hansson L. Br J Clin Pharmacol. 1987;24 Suppl 1(Suppl 1):35S-38S. doi: 10.1111/j.1365-2125.1987.tb03266.x. Br J Clin Pharmacol. 1987. PMID: 3326633 Free PMC article. Review.
• Beta-adrenoceptor antagonists (non-selective as well as beta 1-selective) with partial agonistic activity decrease beta 2-adrenoceptor density in human lymphocytes. Evidence for a beta 2-agonistic component of the partial agonistic activity.

  Brodde OE, Schemuth R, Brinkmann M, Wang XL, Daul A, Borchard U. Brodde OE, et al. Naunyn Schmiedebergs Arch Pharmacol. 1986 Jun;333(2):130-8. doi: 10.1007/BF00506515. Naunyn Schmiedebergs Arch Pharmacol. 1986. PMID: 2875397
• Acute systemic and antiischemic effects of epanolol in patients with coronary artery disease.

  Venneker EH, Remme WJ, van Hoogenhuyze DC, Krauss XH, Bartels GL, Kruijssen DA, Storm CJ, van Schelven D. Venneker EH, et al. Cardiovasc Drugs Ther. 1994 Apr;8(2):211-9. doi: 10.1007/BF00877329. Cardiovasc Drugs Ther. 1994. PMID: 7918133 Clinical Trial.